Calliditas Therapeutics AB (publ)
CALT · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $560 | $295 | $452 | $295 |
| % Growth | 89.4% | -34.6% | 53.3% | – |
| Cost of Goods Sold | $53 | $14 | $22 | $15 |
| Gross Profit | $506 | $281 | $429 | $280 |
| % Margin | 90.5% | 95.3% | 95.1% | 94.9% |
| R&D Expenses | $121 | $151 | $107 | $180 |
| G&A Expenses | $167 | $102 | $95 | $89 |
| SG&A Expenses | $420 | $342 | $293 | $259 |
| Sales & Mktg Exp. | $253 | $240 | $199 | $171 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $541 | $485 | $400 | $439 |
| Operating Income | -$34 | -$204 | $29 | -$160 |
| % Margin | -6.1% | -69% | 6.5% | -54.2% |
| Other Income/Exp. Net | -$8 | -$43 | -$44 | -$5 |
| Pre-Tax Income | -$43 | -$247 | -$14 | -$164 |
| Tax Expense | $5 | -$1 | $4 | $4 |
| Net Income | -$47 | -$246 | -$18 | -$168 |
| % Margin | -8.5% | -83.3% | -4.1% | -57.1% |
| EPS | -1.76 | -9.18 | -0.68 | -6.28 |
| % Growth | 80.8% | -1,250% | 89.2% | – |
| EPS Diluted | -1.76 | -9.18 | -0.68 | -6.28 |
| Weighted Avg Shares Out | 27 | 27 | 27 | 27 |
| Weighted Avg Shares Out Dil | 27 | 27 | 27 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $16 | $0 |
| Interest Expense | $11 | $43 | $0 | $5 |
| Depreciation & Amortization | $3 | $1 | $1 | $1 |
| EBITDA | -$29 | -$203 | $32 | -$159 |
| % Margin | -5.1% | -68.6% | 7.1% | -54% |